Orantinib
| CAS No. | 252916-29-3 | Cat. No. | BCP01984 |
| Name | Orantinib | ||
| Synonyms | TSU68; TSU 68; TSU-68; SU6668; SU 6668; SU-6668; | ||
| Formula | C18H18N2O3 | M. Wt | 310.35 |
| Description | Orantinib, also known as TSU-68；SU6668, is an orally bioavailable receptor tyrosine kinase inhibitor. Orantinib binds to and inhibits the autophosphorylation of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR), thereby inhibiting angiogenesis and cell proliferation. Orantinib also inhibits the phosphorylation of the stem cell factor receptor tyrosine kinase c-kit, often expressed in acute myelogenous leukemia cells. Check for active clinical trials or closed clinical trials using this agent. | ||
| Pathways | Angiogenesis/Protein Tyrosine Kinase | ||
| Targets | PDGFR VEGFR FGFR | ||
|
Characterization of the ERG-regulated Kinome in Prostate Cancer Identifies TNIK as a Potential Therapeutic Target12
Publications Citing of Biochempartner's Orantinib(CAS:252916-29-3) |
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.